Media headlines about Aegerion Pharmaceuticals (NASDAQ:AEGR) have trended somewhat positive on Monday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aegerion Pharmaceuticals earned a news impact score of 0.02 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.677102874307 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Aegerion Pharmaceuticals stock traded up $0.10 on Monday, hitting $1.97. The company had a trading volume of 2,168,900 shares, compared to its average volume of 635,262. The company has a current ratio of 1.02, a quick ratio of 0.67 and a debt-to-equity ratio of -19.22. Aegerion Pharmaceuticals has a 52 week low of $1.23 and a 52 week high of $10.85.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Aegerion Pharmaceuticals (AEGR) Stock Price” was originally published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3343828/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-aegerion-pharmaceuticals-aegr-stock-price.html.
Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.
Receive News & Ratings for Aegerion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.